Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Functional genomics of Caspase-3 deficiency or proficiency in MCF-7 cells or MDA-MB-231 tumors after docetaxel treatment

ABSTRACT: Functional genomics of Caspase-3 deficiency or proficiency in MCF-7 cells or MDA-MB-231 tumors after docetaxel treatment

PROVIDER: PRJNA343932 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR4289870_1.fastq.gz	Fastqsanger.gz
	SRR4289870_2.fastq.gz	Fastqsanger.gz
	SRR4289861_1.fastq.gz	Fastqsanger.gz
	SRR4289861_2.fastq.gz	Fastqsanger.gz
	SRR4289871_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Transcriptome analysis of Caspase-3 inhibited or not MDA-MB-231 tumors after docetaxel treatment

Project description:We report that the inhibition of Caspase-3 reduced angiogenesis in vivo after docetaxel treatment

2019-09-22 | GSE87226 | GEO

IMPRINTS-CETSA Docetaxel and Paclitaxel in MCF-7 cells, 8h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Docetaxel or Paclitaxel using TMT 10 plex.

2024-10-23 | PXD056176 | Pride

IMPRINTS-CETSA Docetaxel and Paclitaxel in MCF-7 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Docetaxel or Paclitaxel using TMT 10 plex.

2024-10-23 | PXD056170 | Pride

Functional genomics of Caspase-3 deficiency or proficiency in MCF-7 cells or MDA-MB-231 tumors after docetaxel treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-09-22 | GSE87227 | GEO

Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.

2011-04-22 | E-GEOD-28784 | biostudies-arrayexpress

Transcriptome analysis of Caspase-3 deficient and proficient MCF-7 cells after docetaxel exposure

Project description:We report that the presence of Caspase-3 induced expression of specific genes

2019-09-22 | GSE87225 | GEO

Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

2011-04-22 | GSE28784 | GEO

Mitochondrial DNA MCF-7 and MDA-MB-231

Project description:Mitochondrial DNA sequence of cell line mixtures MCF-7 and MDA-MB-231

| PRJEB23243 | ENA

Anticancer property of sediment actinomycetes against MCF-7 and MDA-MB-231 cell lines.

Project description:ObjectiveTo investigate the anticancer property of marine sediment actinomycetes against two different breast cancer cell lines.MethodsIn vitro anticancer activity was carried out against breast (MCF-7 and MDA-MB-231) cancer cell lines. Partial sequences of the 16s rRNA gene, phylogenetic tree construction, multiple sequence analysis and secondary structure analysis were also carried out with the actinomycetes isolates.ResultsOf the selected five actinomycete isolates, ACT01 and ACT02 showed the IC50 value with (10.13±0.92) and (22.34±5.82) µg/mL concentrations, respectively for MCF-7 cell line at 48 h, but ACT01 showed the minimum (18.54±2.49 µg/mL) level of IC50 value with MDA-MB-231 cell line. Further, the 16s rRNA partial sequences of ACT01, ACT02, ACT03, ACT04 and ACT05 isolates were also deposited in NCBI data bank with the accession numbers of GQ478246, GQ478247, GQ478248, GQ478249 and GQ478250, respectively. The phylogenetic tree analysis showed that, the isolates of ACT02 and ACT03 were represented in group I and III, respectively, but ACT01 and ACT02 were represented in group II. The multiple sequence alignment of the actinomycete isolates showed that, the maximum identical conserved regions were identified with the nucleotide regions of 125 to 221st base pairs, 65 to 119th base pairs and 55, 48 and 31st base pairs. Secondary structure prediction of the 16s rRNA showed that, the maximum free energy was consumed with ACT03 isolate (-45.4 kkal/mol) and the minimum free energy was consumed with ACT04 isolate (-57.6 kkal/mol).ConclusionsThe actinomycete isolates of ACT01 and ACT02 (GQ478246 and GQ478247) which are isolated from sediment sample can be further used as anticancer agents against breast cancer cell lines.

| S-EPMC3609251 | biostudies-literature

GMI Proficiency Test

Project description:Global Microbial Identifier Proficiency Test

| PRJEB21132 | ENA